Drug Profile
EN 101
Alternative Names: EN-101; MonarsenLatest Information Update: 08 Nov 2010
Price :
$50
*
At a glance
- Originator Hebrew University of Jerusalem
- Developer Amarin Corporation
- Class Oligodeoxyribonucleotides
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis; Inflammatory bowel diseases; Myasthenia gravis
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Inflammatory bowel diseases; Myasthenia gravis
Most Recent Events
- 08 Nov 2010 EN 101 is available for worldwide licensing in myasthenia gravis, inflammatory bowel disease and amyotrophic lateral sclerosis as of 06 Oct 2008. http://www.amarincorp.com
- 18 Jun 2009 Suspended - Preclinical for Amyotrophic lateral sclerosis (PO)
- 18 Jun 2009 Suspended - Preclinical for Inflammatory bowel disease (PO)